Gilead Sciences Financial Statements
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Gilead Sciences revenue and earnings
In fiscal 2025, Gilead Sciences generated $29.44 billion in revenue, up 2.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $8.51 billion (+1672.9% year over year), for a net margin of 28.9% versus a median of 16.8% in the prior 5 years. Gross margin was 78.8% (up from 78.3%) and operating margin 34.0%.
Diluted earnings per share came in at $6.78, up from $0.38. Over the last 5 fiscal years, GILD's revenue has grown at a 3.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Gilead Sciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.44B | 28.75B | 27.12B | 27.28B | 27.30B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B |
| Revenue growth (YoY) | +2.40% | +6.04% | -0.60% | -0.09% | +10.60% | +9.98% | +1.46% | -15.24% | -14.09% | -6.89% |
| Cost of Revenue | 6.23B | 6.25B | 6.50B | 5.66B | 6.60B | 4.57B | 4.67B | 4.85B | 4.37B | 4.26B |
| Gross Profit | 23.21B | 22.50B | 20.62B | 21.62B | 20.70B | 20.12B | 17.77B | 17.27B | 21.74B | 26.13B |
| Operating Expenses | 13.19B | 20.84B | 13.01B | 14.29B | 10.79B | 16.05B | 13.49B | 9.07B | 7.61B | 8.50B |
| Research & Development | 5.80B | 5.91B | 5.72B | 4.98B | 4.60B | 4.93B | 9.11B | 5.02B | 3.73B | 5.10B |
| Selling, General & Admin | 5.77B | 6.09B | 6.09B | 5.67B | 5.25B | 5.15B | 4.38B | 4.06B | 3.88B | 3.40B |
| Operating Income | 10.02B | 1.66B | 7.61B | 7.33B | 9.92B | 4.07B | 4.29B | 8.20B | 14.12B | 17.63B |
| Interest Expense | 1.02B | 977.00M | 944.00M | 935.00M | 1.00B | 984.00M | 995.00M | 1.08B | 1.12B | 964.00M |
| Other Income (Expense) | 798.00M | 6.00M | 198.00M | -581.00M | -639.00M | -1.42B | 1.87B | 676.00M | 523.00M | 428.00M |
| Pretax Income | 9.80B | 690.00M | 6.86B | 5.81B | 8.28B | 1.67B | 5.16B | 7.80B | 13.53B | 17.10B |
| Income Tax | 1.29B | 211.00M | 1.25B | 1.25B | 2.08B | 1.58B | -204.00M | 2.34B | 8.88B | 3.61B |
| Net Income | 8.51B | 480.00M | 5.67B | 4.59B | 6.22B | 123.00M | 5.39B | 5.46B | 4.63B | 13.50B |
| Net Income growth (YoY) | +1672.92% | -91.53% | +23.37% | -26.23% | +4960.98% | -97.72% | -1.26% | +17.87% | -65.72% | -25.44% |
| EPS (Basic) | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 |
| EPS (Diluted) | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 |
| Shares Outstanding (Basic) | 1.24B | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.27B | 1.30B | 1.31B | 1.34B |
| Shares Outstanding (Diluted) | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B |
| EBITDA | 10.39B | 2.04B | 7.96B | 7.65B | 10.25B | 4.36B | 4.54B | 8.43B | 14.36B | 17.81B |
| Gross Margin | 78.83% | 78.26% | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% |
| Operating Margin | 34.04% | 5.78% | 28.05% | 26.87% | 36.32% | 16.49% | 19.10% | 37.06% | 54.10% | 58.02% |
| Net Margin | 28.90% | 1.67% | 20.89% | 16.83% | 22.80% | 50.00% | 23.99% | 24.65% | 17.73% | 44.43% |
This table shows 10 annual periods of Gilead Sciences's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow GILD's reporting calendar. What is a income statement?